SOUTH PLAINFIELD, N.J.,
May 23, 2017 /PRNewswire/ -- PTC
Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation
of new post-hoc analyses from the placebo arm of its ACT DMD Phase
3 trial with respect to the effect of corticosteroids on multiple
measures of disease progression. Siva Narayanan, Vice President and
Global Head, Market Access, Global Value and Health Economics
Division, will present at the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual
International Meeting. The scientific innovation presentation,
"Disease Burden and Treatment Landscape in Duchenne Muscular
Dystrophy (DMD) in the United
States" will be held today at session 3 of the research
poster presentations at the Sheraton Boston Hotel and the John B.
Hynes Veterans Memorial Convention Center in Boston.
"The new approved treatments available to Duchenne muscular
dystrophy patients have the potential to slow the progression of
this devastating disorder," said Siva Narayanan, Vice President and
Global Head, Market Access, Global Value and HE Division at PTC
Therapeutics. "Patients taking deflazacort in the placebo arm of
the ACT DMD study showed a benefit in muscle function which allows
us to estimate a corresponding delay of time to loss of
ambulation1. Studies have shown that delaying loss of
ambulation correlates with a delay in critical other functions.
Slowing the progression of this debilitating disease could improve
the lives of patients and their families2,3."
For more information, visit
https://www.ispor.org/ScientificPresentationsDatabase/Presentation/71977?pdfid=49894.
About PTC Therapeutics
PTC is a global
biopharmaceutical company focused on the discovery, development,
and commercialization of novel medicines using our expertise in RNA
biology. PTC's internally discovered pipeline addresses multiple
therapeutic areas, including rare disorders and oncology. PTC has
discovered all of its compounds currently under development using
its proprietary technologies. Since its founding nearly 20 years
ago, PTC's mission has focused on developing treatments to
fundamentally change the lives of patients living with rare genetic
disorders. The company was founded in 1998 and is headquartered in
South Plainfield, New Jersey. For
more information please visit www.ptcbio.com.
For More
Information:
Investors:
Emily
Hill
+ 1 (908) 912-9327
ehill@ptcbio.com
Media:
Jane Baj
+1 (908) 912-9167
jbaj@ptcbio.com
Forward Looking Statements:
All statements, other than
those of historical fact, contained in this release are
forward-looking statements, including statements regarding the
future expectations, plans and prospects for PTC; the clinical
utility and potential advantages of deflazacort; the timing,
results and conduct of PTC's clinical trials and studies of
deflazacort for the treatment of DMD; PTC's strategy, future
operations, future financial position, future revenues or projected
costs; and the objectives of management. Other
forward-looking statements may be identified by the words
"guidance", "plan," "anticipate," "believe," "estimate," "expect,"
"intend," "may," "target," "potential," "will," "would," "could,"
"should," "continue," and similar expressions.
PTC's actual results, performance or achievements could differ
materially from those expressed or implied by forward-looking
statements it makes as a result of a variety of risks and
uncertainties, including the factors discussed in the "Risk
Factors" section of PTC's most recent Quarterly Report on Form 10-Q
as well as any updates to these risk factors filed from time to
time in PTC's other filings with the SEC. You are urged to
carefully consider all such factors.
The forward-looking statements contained herein represent PTC's
views only as of the date of this press release and PTC does not
undertake or plan to update or revise any such forward-looking
statements to reflect actual results or changes in plans,
prospects, assumptions, estimates or projections, or other
circumstances occurring after the date of this press release except
as required by law.
1. Treat-NMD. http://www.treat-nmd.eu/downloads/file/
meetings/2013/workshop/Session1/McDonald_NH.pdf. [Accessed
May 10, 2017]
2. Ryder et al. Orphanet J Rare Dis. 2017; 12(1):79.
3. Wei Y et al. J of Neuromuscul Dis. 2015;2(3):313-324.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-analysis-of-act-dmd-placebo-data-on-corticosteroids-presented-at-international-society-for-pharmacoeconomics-and-outcomes-research-22nd-annual-international-meeting-300462182.html
SOURCE PTC Therapeutics, Inc.